====== Nicholas Brousseau ======

{{ ::64996036_159963f2173d2d-0e27-4f3c-b4a9-6b33760fea81_original_1_copy.png?200|}}

Dr. **Nicholas Brousseau** is a Canadian preventative medicine specialist based in [[canada:quebec:Quebec City]], [[canada:Quebec]].

===== Education =====

Brousseau completed his education at [[Laval University]] in 2011.(([[Public Health Agency of Canada]]. (2022, February 25). //National Advisory Committee on Immunization (NACI): Membership and representation.// Government of Canada. https://web.archive.org/web/20220318105951/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/naci-membership-representation.html#fn1-rf))

===== Career and Affiliations =====

==== Public Health England ====

Following his education, he completed a research fellowship on vaccine-preventable diseases in the [[Centre for Infectious Disease Surveillance and Control]] and the [[Immunisation, Hepatitis and Blood Safety Department]] at [[Public Health England]] in London. In that position, he published research on [[influenza]] and pneumococcal vaccination, as well as [[hepatitis B]] infection.((Green, H. K., Brousseau, N., Andrews, N., Selby, L., & Pebody, R. (2016). //Illness absenteeism rates in primary and secondary schools in 2013–2014 in England: was there any impact of vaccinating children of primary-school age against influenza?// Epidemiology and Infection, 144(16), 3412–3421. https://doi.org/10.1017/s0950268816001680)) ((Brousseau, N., Andrews, N., Waight, P., Stanford, E., Newton, E., Almond, R., Slack, M. P. E., Miller, E., Borrow, R., & Ladhani, S. N. (2015). //Antibody Concentrations Against the Infecting Serotype in Vaccinated and Unvaccinated Children With Invasive Pneumococcal Disease in the United Kingdom, 2006–2013.// Clinical Infectious Diseases, 60(12), 1793–1801. https://doi.org/10.1093/cid/civ164)) ((Brousseau, N., Murphy, D. G., Gilca, V., Larouche, J., Mandal, S., & Tedder, R. S. (2017). //Acute hepatitis B virus infection with delayed appearance of hepatitis B core antibody in an immunocompromised patient: a case report.// Journal of Medical Case Reports, 11(1). https://doi.org/10.1186/s13256-017-1264-9)) ((Brousseau, N., Green, H. K., Andrews, N., Pryse, R., Baguelin, M., Sunderland, A., Ellis, J., & Pebody, R. (2015). //Impact of influenza vaccination on respiratory illness rates in children attending private boarding schools in England, 2013–2014: a cohort study.// Epidemiology and Infection, 143(16), 3405–3415. https://doi.org/10.1017/s0950268815000667))

==== Institut national de santé publique du Québec ====

Brousseau joined the [[Quebec Ministry of Health and Social Services]] in 2015.((//Nicholas Brousseau.// Université de Laval. Retrieved May 21, 2022, from https://archive.ph/eUtra))
==== Quebec Immunization Committee ====

He has been a Member of the [[Quebec Immunization Committee]] since 2016.((//Comité sur l’immunisation du Québec (CIQ).// INSPQ. Retrieved March 22, 2022, from https://archive.ph/9eVKx))
==== Laval University ====

Brousseau joined the [[Centre de recherche du CHU de Québec]] at [[Laval University]] in 2019, where is also a Clinical Associate Professor.

==== National Advisory Committee on Immunization ====

Brousseau is a member of the [[National Advisory Committee on Immunization]].(([[Public Health Agency of Canada]]. (2022, February 25). //National Advisory Committee on Immunization (NACI): Membership and representation.// Government of Canada. https://web.archive.org/web/20220318105951/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/naci-membership-representation.html#fn1-rf))

===== Research =====

Brousseau conducts research on vaccine-preventable diseases. His areas of expertise are vaccination against [[pertussis]], [[tetanus]], [[pneumococcus]], [[influenza]] and [[COVID-19]] (immunogenicity, efficacy and impact of vaccination). He also conducts work on the optimization of vaccination services in Quebec. In 2020, he established a study on the seroprevalence of antibodies against the [[SARS-CoV-2]] in health care workers in 10 hospital centers in Quebec.

==== Funding ====

Research funding for Brousseau's studies has come from [[pharmaceutical_companies:Merck]] and the [[Quebec Ministry of Health and Social Services]].(([[Public Health Agency of Canada]]. (2022, February 25). //National Advisory Committee on Immunization (NACI): Membership and representation.// Government of Canada. https://web.archive.org/web/20220318105951/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/naci-membership-representation.html#fn1-rf))

===== Media =====

==== Presentations ====

Brousseau has given presentations at scientific conferences, including the [[Canadian Immunization Conference]] (CIC).